Abstract
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder and the most commonly diagnosed cause of dementia, and it is the fifth leading cause of death among people aged 65 and older. During the years, the early diagnosis of AD patients has been a significant concern for researchers, in view of the fact that early diagnosis not only can lead to saving lives of the AD patients but also could bring a considerable amount of saving in health and long-term care expenditures for both people and the government. Mild cognitive impairment (MCI), defined as a transitional state between being healthy and having AD, is considered an established risk factor for AD. Hence, an accurate and reliable diagnosis of MCI and, consequently, discrimination between healthy people, MCI individuals, and AD patients can play a crucial role in the early diagnosis of AD. In recent years, analysis of blood gene expression data has been grabbed more attention than the conventional AD diagnosis method because it provides the opportunity to investigate the biochemical pathways, cellular functions, and regulatory mechanisms for finding the key genes associated with MCI and AD. Therefore, in this study, we employed blood gene expression data from Alzheimer’s Disease Neuroimaging Initiative (ADNI), two feature selection methods for determining the most prominent genes related to MCI and AD, and three classifiers for the most accurate discrimination between three groups of healthy, MCI and AD. The proposed method yielded the selection of top ten genes from more than 49,000 genes and the best overall classification result between healthy and AD patients with average values of the area under the curve (AUC) of 0.77 ± 0.08. Furthermore, gene ontology (GO) analysis revealed that four genes were enriched with the GO terms of regulation of cell proliferation, negative regulation of cell population proliferation, signaling receptor binding, biological adhesion, and cytokine production.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no funding to support this project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Because we used an online dataset there was no need of IRB
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data we used is available online and can be download from the following link: “http://adni.loni.usc.edu/data-samples/data-types/genetic-data/ webiste.